Newsroom

October 2015

• Press release Oct 29, 2015

  Novartis Foundation and partners launch new hypertension program in Ghana

  Community-based Hypertension Improvement Project (ComHIP) is an innovative healthcare model designed to improve hypertension management and control Screening and treatment is shifted to the…
• 
  Story Oct 27, 2015 Discovery

  Stepping toward regenerative medicine for diabetes

  Discovery points toward treatment options beyond insulin injections

• 
  Story Oct 27, 2015 Discovery

  Compounds spur insulin-producing cells to replicate in the lab

• Press release Oct 27, 2015

  Novartis a réalisé, au troisième trimestre, une forte hausse de sa marge core (tcc) et continué de renforcer son pipeline, confirmant ainsi ses prévisions pour l'exercice

  Croissance solide (tcc[1]), au T3, des ventes, du résultat opérationnel core et du BPA core des activités poursuivies[2] Chiffre d'affaires net d'USD 12,3 milliards (-6%, +6% tcc) Résultat…
• Press release Oct 27, 2015

  Novartis steigert die Kerngewinnmarge (kWk) im dritten Quartal kräftig, stärkt erneut die Pipeline und ist auf Kurs für die Jahresprognose

  Solides Wachstum (kWk[1]) im dritten Quartal beim Umsatz, operativen Kernergebnis und Kerngewinn pro Aktie der fortzuführenden Geschäftsbereiche[2]: Der Nettoumsatz beläuft sich auf USD 12,3…
• Press release Oct 27, 2015

  Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance

  Solid growth (cc[1]) in Q3 sales, core operating income, core EPS for continuing operations[2] Net sales were USD 12.3 billion (-6%, +6% cc) Operating income was USD 2.2 billion (-18%, +2% cc) Core…
• Press release Oct 23, 2015

  Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritis

  Cosentyx (secukinumab) is recommended for approval in Europe for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients  Cosentyx demonstrated rapid onset of…
• Press release Oct 21, 2015

  Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and Palobiofarma

  With four programs currently in clinical trials and five more expected to enter the clinic by the end of 2016, Novartis has rapidly built a robust portfolio of programs focused on stimulating the…
• 
  Story Oct 19, 2015 Discovery

  Clinical trials make a move toward mice

  By growing human tumors in mice, NIBR develops a unique system that seeks to mimic clinical trials of cancer drugs

• 
  Story Oct 15, 2015 Access to Healthcare

  Delivering access: first launch in Kenya

  Chronic diseases kill 38 million people per year worldwide; almost three-quarters of those deaths occur in low- and middle-income countries. It’s time to act.

• 
  Story Oct 15, 2015 Discovery

  Getting down to the roots of Alzheimer’s disease

  Experimental treatments for Alzheimer’s disease put the amyloid cascade hypothesis to the test.

• 
  Story Oct 15, 2015 Discovery

  Stopping Alzheimer's disease before it starts

  Novartis collaborates with the Banner Alzheimer’s Institute to test treatments for preventing Alzheimer’s disease.